Processing...
Clinical Trials for Small Cell Lung Cancer
Search
Search
There are 425 active trials for advanced/metastatic small cell lung cancer.
Click on a trial to see more information.
425 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with advanced, refractory solid tumors (ECOG 0–1) receive an allogeneic, off‑the‑shelf iPSC‑derived CAR T product (FT836) targeting stress‑inducible MICA/MICB (engineered to reduce antigen shedding) as monotherapy or combined with trastuzumab (HER2), cetuximab (EGFR), and/or paclitaxel. Multi‑arm cohorts assess safety and preliminary activity to establish RP2D for the combination regimens.
ClinicalTrials.gov ID: NCT07216105
TrialFetch AI summary: Adults with advanced/metastatic NSCLC, SCLC, endometrial cancer, or triple‑negative breast cancer after standard options receive LY4175408, an investigational PTK7‑targeted antibody–drug conjugate delivering an exatecan (topoisomerase I inhibitor) payload, given IV every 21 days. Requires ECOG 0–1 and measurable disease (for later cohorts); excludes prior PTK7 topoisomerase I ADCs, uncontrolled CNS metastases, significant cardiac disease, ILD/pneumonitis, active infection, and prolonged QTc.
ClinicalTrials.gov ID: NCT07046923
TrialFetch AI summary: Adults with advanced solid tumors including HNSCC, pancreatic adenocarcinoma, NSCLC, HR+/HER2− breast cancer post‑CDK4/6 inhibitor, or platinum‑resistant high‑grade serous ovarian/related cancers receive the oral CDK7 inhibitor GTAEXS617 (transcription/cell‑cycle regulator) as monotherapy or combined with standard-of-care regimens. Eligible patients have ECOG 0–1 and adequate organ function; study explores safety, PK, and preliminary activity with tumor biopsies required.
ClinicalTrials.gov ID: NCT05985655
TrialFetch AI summary: Monotherapy ALE.P03, a Claudin‑1–targeted antibody–drug conjugate that delivers a topoisomerase I inhibitor payload, for adults with centrally confirmed CLDN1-positive advanced/metastatic solid tumors limited to mCRC, intrahepatic cholangiocarcinoma, squamous NSCLC, urothelial carcinoma, or cervical squamous cell carcinoma. Requires RECIST-measurable, ECOG 0–1 disease with prior standard therapy (dose escalation: refractory/intolerant to all; expansion/phase II: 1–2 prior lines and prior targeted therapy if actionable drivers), excluding active CNS metastases and significant ILD/pneumonitis.
ClinicalTrials.gov ID: NCT07169734
TrialFetch AI summary: Adults with advanced/metastatic solid tumors who have exhausted standard options receive IV TJ101, a bispecific EGFR/B7-H3 antibody–drug conjugate, every 3 weeks in dose escalation with biomarker-driven expansion cohorts. Excludes prior topoisomerase I inhibitor or TOP1i-ADC exposure, active ILD/pneumonitis, significant ocular or uncontrolled cardiovascular disease, and active CNS disease unless treated and stable.
ClinicalTrials.gov ID: NCT07181473
TrialFetch AI summary: Adults with advanced/metastatic colorectal adenocarcinoma, NSCLC, or pancreatic ductal adenocarcinoma after at least one prior systemic therapy receive IV PHN-012, a first-in-human investigational antibody–drug conjugate (target undisclosed; exclusion suggests possible topoisomerase‑I payload). Open-label dose escalation with tumor-specific expansion; requires measurable disease, ECOG 0–1, adequate organs, and available tissue; excludes prior topo‑I ADCs, unstable CNS mets, and active/past ILD/pneumonitis.
ClinicalTrials.gov ID: NCT07127874
TrialFetch AI summary: Adults with advanced/metastatic MUC1-overexpressing solid tumors: dose-escalation/expansion of M0324, an investigational MUC1-conditional CD40 agonist antibody, as monotherapy (post–standard therapy) or combined with pembrolizumab after prior ICI progression; separate cohort tests M0324 plus mFOLFIRINOX as first-line therapy for metastatic pancreatic ductal adenocarcinoma. Key exclusions include significant GI inflammation (e.g., chronic grade ≥2 diarrhea/IBD) and uncontrolled cardiovascular disease.
ClinicalTrials.gov ID: NCT07166601
TrialFetch AI summary: Adults with homozygous MTAP-deleted solid tumors (ECOG 0–1) receive oral BAY 3713372, an MTAP-selective, second-generation PRMT5 inhibitor exploiting synthetic lethality, with monotherapy dose escalation and expansions in all MTAP-deleted tumors plus focused cohorts in NSCLC and PDAC. Expansion includes BAY 3713372 alone and in combinations for NSCLC and PDAC; key cardiac comorbidities are excluded.
ClinicalTrials.gov ID: NCT06914128
TrialFetch AI summary: Adults with FRα-positive metastatic/recurrent lung adenocarcinoma and malignant pleural effusion (ECOG 0–1, prior systemic therapy) receive cyclophosphamide/fludarabine lymphodepletion followed by a single intrapleural infusion of autologous MOv19-BBz CAR T cells targeting folate receptor‑alpha (second‑generation CAR with 4‑1BB/CD3ζ). Candidates must be eligible for standard checkpoint inhibitors (which may start ≥28 days post‑CAR T) and have controlled CNS disease; key exclusions include extensive parenchymal lung involvement beyond one lobe, significant undrainable effusion, ILD/pneumonitis, active hepatitis, and autoimmune disease requiring immunosuppression.
ClinicalTrials.gov ID: NCT07116057
TrialFetch AI summary: Adults with previously treated, locally advanced/metastatic small cell lung cancer or other neuroendocrine tumors (e.g., LCNEC, NEPC, high‑grade GI‑NET, Merkel cell) receive BL‑M14D1, an investigational DLL3‑targeted antibody–drug conjugate with a topoisomerase I inhibitor payload, given IV every 21 days. Suitable for ECOG 0–1 patients post‑standard therapy (SCLC requires prior platinum); excludes prior topo‑I ADCs, significant cardiac/QTc issues, ILD/pneumonitis, active CNS disease, and uncontrolled infections.
ClinicalTrials.gov ID: NCT07080242